Fair and equitable treatment in biotech investments

Introduction

Fair and Equitable Treatment (FET) is an important principle of international investment law that protects foreign investors against arbitrary, discriminatory, unfair or unreasonable treatment by host states. In the biotechnology sector, this principle has particular significance because investments often involve substantial financial resources, advanced scientific research, intellectual property, pharmaceutical manufacturing, genetic technologies and long-term research and development projects.

Biotechnology investments frequently depend on government approvals, regulatory permissions, clinical trial authorisations, environmental clearances and intellectual property protection. Sudden regulatory changes, discriminatory licensing decisions, unreasonable delays or arbitrary cancellation of approvals may adversely affect foreign investors.

FET provisions are commonly included in Bilateral Investment Treaties (BITs) and other international investment agreements. They seek to maintain a balance between protecting foreign investors and preserving the sovereign right of states to regulate biotechnology activities in the public interest, particularly for public health, environmental protection and biosafety.

Meaning and scope of fair and equitable treatment

Fair and Equitable Treatment is a standard of protection granted to foreign investors under international investment agreements. It requires host states to exercise their regulatory and administrative powers fairly, transparently and consistently with applicable international obligations.

In biotechnology investments, FET may apply to foreign companies investing in pharmaceutical manufacturing, vaccine production, agricultural biotechnology, genetic research, medical technology and biological research facilities.

The principle generally addresses the following elements:

Protection against arbitrary conduct: Government decisions should not be unreasonable or based on improper considerations.

Transparency: Regulatory procedures and investment-related requirements should be sufficiently clear and accessible.

Due process: Investors should receive fair administrative and legal procedures.

Non-discrimination: Investors should not face unjustified discriminatory treatment.

Legitimate expectations: Specific representations or assurances made by the government may create expectations deserving legal protection, depending on the circumstances.

Regulatory consistency: Government authorities should exercise their powers in a predictable and legally justified manner.

Importance of FET in biotechnology investments

Biotechnology investments are particularly sensitive to regulatory uncertainty because research and development activities often require substantial capital and long development periods.

For example, a foreign pharmaceutical company may establish a vaccine manufacturing facility after obtaining government approvals. If the government subsequently cancels its permissions without adequate legal justification or procedural fairness, the investor may claim that its FET protections have been violated under the applicable investment treaty.

Similarly, a foreign biotechnology company investing in genetically modified agricultural research may face regulatory restrictions concerning environmental safety, biosafety approvals and commercialisation.

However, FET does not guarantee that investors will always receive regulatory approval or remain protected from legitimate changes in public policy.

Legal framework governing FET in India

India's approach to FET is influenced by its bilateral investment treaties, domestic legislation and international investment arbitration.

1. Indian Model Bilateral Investment Treaty, 2015

India introduced its Model BIT in 2015 to establish a more balanced framework for protecting foreign investments while preserving the government's regulatory authority.

The Model BIT provides a narrower and more carefully defined approach to investment protection than many traditional investment treaties.

Article 3 deals with national treatment and most-favoured-nation treatment, while Article 4 addresses fair and equitable treatment and provides protection against specified forms of conduct, including denial of justice, fundamental breach of due process, targeted discrimination and manifestly abusive treatment.

This framework is relevant to biotechnology investors because it seeks to balance investment protection with the government's authority to regulate public health, environmental safety and technological development.

2. Foreign Exchange Management Act, 1999

The Foreign Exchange Management Act, 1999, regulates foreign exchange transactions and provides the legal framework for foreign investment-related financial activities in India.

Foreign biotechnology companies investing in India must comply with applicable foreign investment rules and reporting requirements.

3. Companies Act, 2013

The Companies Act, 2013, governs the incorporation, administration and corporate responsibilities of companies operating in India.

Foreign biotechnology investors establishing Indian subsidiaries or joint ventures must comply with applicable corporate governance and disclosure requirements.

4. Patents Act, 1970

The Patents Act, 1970, provides the legal framework for patent protection in India.

Biotechnology investors may seek protection for eligible inventions involving pharmaceutical formulations, diagnostic technologies, biological processes and other patentable innovations, subject to statutory exclusions and requirements.

5. Competition Act, 2002

The Competition Act, 2002, regulates anti-competitive agreements, abuse of dominant position and combinations.

It is relevant to biotechnology investments because mergers, acquisitions, licensing arrangements and market practices may raise competition-related concerns.

Application of FET to biotechnology investments

1. Pharmaceutical and vaccine investments

Foreign pharmaceutical companies invest in research, manufacturing facilities and vaccine development. Unreasonable administrative delays, arbitrary cancellation of licences or discriminatory regulatory treatment may raise FET concerns.

However, legitimate regulatory restrictions based on scientific evidence and public health requirements do not automatically violate FET.

2. Agricultural biotechnology investments

Foreign investors may participate in genetically modified crop research, agricultural biotechnology and seed development.

FET may become relevant where government authorities impose restrictions inconsistently or act arbitrarily. At the same time, governments retain the right to regulate agricultural biotechnology to protect biodiversity, farmers and environmental safety.

3. Genetic research and medical technology

Biotechnology companies investing in genetic testing, gene therapies and medical research require regulatory clarity and reliable administrative procedures.

Unjustified interference with legally protected investments may raise treaty-related concerns.

4. Intellectual property and technology licensing

Intellectual property is an important component of biotechnology investments. Arbitrary administrative interference with legally recognised intellectual property rights may raise investment protection issues, depending on the applicable treaty and circumstances.

Relationship between FET and the state's right to regulate

FET does not prevent governments from introducing new laws or changing existing regulations.

Biotechnology is closely connected with public health, environmental protection, food safety and ethical research. Therefore, governments must retain sufficient authority to regulate these activities.

For example, a government may restrict a biotechnology product after receiving new scientific evidence concerning its safety. Such action may be legitimate even if it reduces the investor's expected profits.

Investment tribunals generally examine whether the government's conduct was arbitrary, discriminatory, disproportionate or procedurally unfair rather than simply determining whether the investor suffered economic loss.

Relevant case laws and international arbitration decisions

1. Tecmed v. Mexico (2003)

The tribunal examined the denial of renewal of an operating permit for a hazardous waste landfill facility.

It discussed the importance of transparency, consistency and the protection of legitimate expectations under the FET standard.

Relevance: The decision is relevant to biotechnology companies operating regulated laboratories, pharmaceutical facilities and biological manufacturing units. Regulatory decisions affecting such investments should be exercised fairly and transparently.

2. Saluka Investments BV v. Czech Republic (2006)

The tribunal examined the treatment of a foreign investment in the Czech banking sector.

It recognised that FET requires a host state to maintain a reasonable balance between the interests of foreign investors and its legitimate regulatory objectives.

Relevance: Biotechnology investors cannot expect complete freedom from regulatory changes. Governments may introduce measures to protect public health and environmental safety, provided they act consistently with applicable investment treaty obligations.

3. Waste Management Inc. v. Mexico (2004)

The tribunal examined the treatment of a foreign investor involved in municipal waste management.

It explained that FET may be violated through conduct involving arbitrariness, gross unfairness, discrimination or denial of due process.

Relevance: This decision provides useful principles for biotechnology investors facing arbitrary administrative decisions, unfair licensing procedures or discriminatory treatment.

4. Philip Morris Brands Sàrl v. Uruguay (2016)

The tribunal considered investment treaty claims concerning Uruguay's tobacco-control regulations.

It recognised the importance of the state's regulatory authority to protect public health and rejected the investor's claims.

Relevance: The decision is particularly important for pharmaceutical and biotechnology investments because it demonstrates that governments may introduce legitimate public health regulations without automatically violating FET protections.

5. White Industries Australia Limited v. Republic of India (2011)

The tribunal examined an investment dispute involving delays in the Indian judicial system and the effectiveness of remedies available to the investor.

It found that India had breached the applicable BIT's obligation concerning effective means of asserting claims and enforcing rights.

Relevance: The decision highlights the importance of timely and effective legal remedies for foreign biotechnology investors involved in contractual, licensing or intellectual property disputes.

Challenges in applying FET to biotechnology investments

The application of FET in biotechnology investments creates several legal and regulatory challenges.

First, biotechnology regulations frequently change because of scientific developments and emerging health and environmental concerns. Investors may find it difficult to distinguish legitimate regulatory changes from arbitrary government action.

Other important challenges include:

Uncertainty concerning the scope of legitimate expectations.

Conflicts between investment protection and public health.

Delays in biotechnology licensing and regulatory approvals.

Disputes involving patents and technology transfers.

Differences between national biosafety standards.

Government restrictions on sensitive biological technologies.

Difficulties in determining compensation for investment losses.

These challenges require clear investment agreements, transparent administrative procedures and effective dispute-resolution mechanisms.

Recommendations for strengthening FET protection

India can strengthen biotechnology investment confidence while maintaining its regulatory independence through several measures:

Establishing transparent biotechnology investment approval procedures.

Providing clear regulatory guidelines for pharmaceutical and genetic research.

Ensuring consistent and non-discriminatory administrative decisions.

Improving the efficiency of investment dispute-resolution mechanisms.

Protecting legitimate intellectual property rights.

Maintaining scientifically justified public health and environmental regulations.

Encouraging transparent communication between investors and regulatory authorities.

Conclusion

Fair and Equitable Treatment is an important principle for promoting international investment in the biotechnology sector. It protects foreign investors against arbitrary, discriminatory and procedurally unfair government conduct while allowing states to regulate biotechnology activities in the public interest. India's Model BIT, 2015, provides an important framework for balancing investment protection with sovereign regulatory authority. Judicial and arbitral decisions such as Tecmed v. Mexico (2003), Saluka Investments v. Czech Republic (2006), Philip Morris v. Uruguay (2016) and White Industries v. India (2011) demonstrate the significance of transparency, legitimate expectations, due process and regulatory autonomy. A balanced FET framework can strengthen investor confidence, encourage biotechnology innovation and support responsible international investment without compromising public health, environmental protection or national interests.